August 7, 2026 · Form 4 insider transaction
AH Bio Fund IV, L.P. bought 1,100,000 shares of Braveheart Bio, Inc. at $18.00 per share, a transaction worth $19.80M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.; (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.